Evaluating Sterile Injectable CMO/CDMO Projects

Sterile injectable projects combine high patient risk, demanding contamination controls and complex interfaces among development, manufacturing, testing, registration and supply. The first task is therefore not to exchange a complete technical package. It is to determine, using non-confidential information, whether the project is suitable for structured due diligence.

1. Separate a platform match from a project fit

A manufacturing platform may cover sterile lyophilized powder injections, sterile powder injections or terminally sterilized small-volume injections. That information is useful, but it does not establish readiness for a particular product. Product fit also depends on formulation characteristics, sterilization strategy, container-closure system, batch size, equipment train, material compatibility, analytical methods, target market and current authorization status.

The initial screen should answer a limited set of questions: What is the dosage form? Which market is targeted? Is the product in development, transfer, registration or commercial supply? What batch and presentation are expected? Which party owns the dossier, process knowledge and regulatory responsibility? What timing is required? These facts can normally be discussed without disclosing formulas, detailed process parameters or other trade secrets.

2. Define whether the project is CMO, CDMO or technology transfer

The labels overlap, but the operating model matters. A CMO project typically begins with a more mature product and process, while a CDMO project may require formulation, analytical, process-development or scale-up work before commercial manufacturing. A technology-transfer project focuses on reproducing an established product, process or analytical procedure at a receiving site. WHO expects technology transfer to be organized, documented and governed through written responsibilities, gap analysis, risk management and evidence that the receiving unit can routinely reproduce the transferred work. [1]

Before costing or scheduling, the parties should agree on the starting maturity level and the expected end state. “Manufacture this product” is not a sufficient scope. A usable scope describes the deliverables, data package, study responsibilities, target markets, acceptance criteria and decisions required to move to the next stage.

3. Conduct technical due diligence across eight dimensions

1. Product and formulation. Identify critical quality attributes, material sensitivities, known degradation pathways, reconstitution behavior where relevant and the existing control strategy.
2. Sterility assurance. Confirm whether the product is terminally sterilized or aseptically processed, then assess the required contamination controls, sterilization or filtration strategy, interventions, hold times and container-closure integrity.
3. Facility and equipment. Compare formulation, filling, lyophilization or terminal-sterilization equipment, utilities, cleanroom design, flows, automation, scale and the proposed manufacturing train.
4. Materials and packaging. Review active ingredient, excipients, primary packaging, supplier status, specifications, extractables or compatibility questions and sourcing constraints.
5. Analytical control. Map methods, reference standards, method validation or transfer status, microbiological testing, sample handling and laboratory capacity.
6. Process understanding. Identify critical parameters, proven or studied ranges, development history, deviations, scale-up assumptions and the evidence supporting the control strategy.
7. Regulatory status. Compare the approved or proposed dossier, market-specific commitments, changes created by the new site and the required submission or inspection pathway.
8. Supply model. Test demand, campaign size, lead time, release pathway, storage, transport, safety stock, business continuity and the economics of the proposed scale.

4. Treat sterility assurance as a system

FDA’s aseptic-processing guidance describes controls covering buildings and facilities, personnel, components and containers, sterilization, media fills, environmental monitoring, laboratory controls and documentation. No single test can compensate for a weak process. [2] Terminally sterilized products and aseptically processed products also require different risk models; the correct route must be established from product characteristics and applicable requirements, not selected for convenience.

For lyophilized products, the assessment may also need to cover freezing and drying behavior, loading pattern, equipment capability, cycle transfer, stopper position, chamber control and container-closure integrity. The necessary study package is product-specific. Public identification of a lyophilization platform should never be interpreted as an automatic commitment to manufacture every lyophilized product.

5. Put quality governance in place before technical execution

FDA’s contract-manufacturing guidance explains that quality agreements can define and document the manufacturing activities of the parties under CGMP. The agreement should support, rather than replace, the applicable responsibilities of each organization. [3] It should identify ownership and timing for documents, materials, specifications, method transfer, validation, batch review, release support, deviations, out-of-specification results, change control, complaints, recalls, audits and regulatory communication.

ICH Q10 provides a lifecycle quality-system model, while ICH Q9(R1) supports science-based and proportionate quality-risk management. Together they point toward a practical rule: important decisions should be traceable to evidence, defined responsibility and a documented risk rationale. [4] [5]

6. Use evidence-based stage gates

7. Protect speed by defining the stop conditions

A project should pause when critical product knowledge is unavailable, the proposed process does not fit the facility, the target-market pathway is unresolved, the analytical package cannot support decisions, the commercial scale is not viable, or responsibilities remain ambiguous. Early stop conditions protect both parties from spending heavily on a program that cannot reach a defensible technical and regulatory outcome.

Conversely, a good preliminary assessment creates speed. It allows the parties to focus confidential review on the few questions that determine feasibility, establish a realistic critical path and reserve manufacturing or development resources only after the evidence supports doing so.

Authoritative sources

1. WHO TRS 1044, Annex 4 — Technology transfer in pharmaceutical manufacturing
2. U.S. FDA — Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice
3. U.S. FDA — Contract Manufacturing Arrangements for Drugs: Quality Agreements
4. ICH Q10 — Pharmaceutical Quality System
5. ICH Q9(R1) — Quality Risk Management
6. U.S. FDA — Process Validation: General Principles and Practices

This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.